TICKERNERD
Menu
ENTAENTAHealthcare · Biotechnology

ENTA Stock Forecast: Enanta Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$13
+2.05% on the day

The 5 Wall Street analysts covering Enanta Pharmaceuticals, Inc. hold a median 12-month price target of $20 — +54.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 12 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$377.5M
Ticker Nerd rank
86 / 100
Median analyst target
$20
Analysts covering
5
Revenue$14.4M−21.6% y/y
Operating income−$17.2M
Net income−$19.5M
Free cash flow−$10.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.6%
1M
−4.1%
YTD
−17.8%
1Y
+49.7%
From 52W high
−23.1%
From 52W low
+80.8%
$7
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ENTA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Enanta Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Quality
89
Momentum
78
Value
76
Accruals
73
Issuance
66
Size
57
Volatility
39
Revisions
28

Growth (93): Sales and profits are climbing, and climbing faster than before.

Revisions (28): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ENTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$8$10$12$14$16$18$20Oct 25Jan 26Apr 26Jul 26ENTAHigh $20Median $20Low $19

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $19Median $20High $20

The green dot is the last close — the median target sits +54.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
23 June 2026HC Wainwright & Co.ReiteratesBuy$20
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
14 Nov 2025JP MorganInitiatesOverweight—
1 Oct 2025JefferiesUpgradeBuy—
30 Sept 2025WestPark CapitalMaintainsBuy—
15 Sept 2025Evercore ISI GroupMaintainsOutperform—
2 Sept 2025WestPark CapitalInitiatesBuy—
12 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
28 July 2025HC Wainwright & Co.AssumesBuy$20
3 June 2025JMP SecuritiesMaintainsMarket Outperform—
14 May 2025JMP SecuritiesMaintainsMarket Outperform—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
24 Dec 2024HC Wainwright & Co.MaintainsBuy—
26 Nov 2024BairdMaintainsOutperform—
26 Nov 2024JMP SecuritiesReiteratesMarket Outperform—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—
9 Oct 2024JMP SecuritiesReiteratesMarket Outperform—
27 Sept 2024JMP SecuritiesReiteratesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ENTA appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ENTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Enanta Pharmaceuticals, Inc. returned +49.7% against +17.5% for the S&P 500, dividends included.

ENTA vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Oct 25Jan 26Apr 26Jul 26ENTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Enanta Pharmaceuticals, Inc. (ENTA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.4×

Cheaper than 88% of US stocks

Price / sales
5.8×

Cheaper than 22% of US stocks

Price / book
3.7×

Cheaper than 27% of US stocks

EV / EBITDA
−6.9×

Cheaper than 82% of US stocks

Growth & margins
Revenue growth (YoY)
−21.6%

Higher than 11% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−120.0%

Higher than 13% of US stocks

Net margin
−96.9%

Higher than 6% of US stocks

Returns & dividend
Return on equity
−70.1%

Higher than 17% of US stocks

Return on assets
−12.3%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Enanta Pharmaceuticals, Inc. (ENTA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enanta Pharmaceuticals, Inc. has a market value of $377.5M and an enterprise value of $370.0M.

  • Revenue in the twelve months to 30 June 2026: $65.3M. The latest quarter shrank 21.6% year on year.

  • Net income over the same four quarters: −$63.2M, a −96.9% net margin.

  • Diluted earnings per share, trailing twelve months: $−2.41.

  • Free cash flow in the twelve months to 30 June 2026: −$36.9M.

  • Shares outstanding: 29.1M.

  • Trailing P/E: −3.4×; forward P/E: −5.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Enanta Pharmaceuticals, Inc. employs 120 people — $544K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ENTA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENTAEnanta Pharmaceuticals, Inc.$377.5M
86
TTRXTurn Therapeutics, Inc.$373.7M
16
INDPIndaptus Therapeutics, Inc.$369.1M
23
EVMNEvommune, Inc.$379.6M
10
PRLDPrelude Therapeutics, Inc.$365.6M
95
RCKTRocket Pharmaceuticals, Inc.$362.5M
55
CMPXCompass Therapeutics, Inc.$360.2M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Enanta Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ENTA news & analysis

Enanta Pharmaceuticals to Participate in September Investor Conferences

Business Wire · 1 Sept 2026neutral

Enanta Pharmaceuticals announced that members of its management will participate in two investor conferences in September: the Baird 2026 Global Healthcare Conference (fireside chat on September 15, 2026) and the H.C. Wainwright 28th Annual Global Investment Conference. The company is a clinical-stage biotechnology firm developing small molecule drugs for viral infections and immunological diseases.

Why it matters — Management's participation in these conferences gives ENTA watchers an opportunity to hear directly from company leadership about their clinical-stage programs.

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Zacks Investment Research · 10 Aug 2026negative

Enanta Pharmaceuticals reported a fiscal-third-quarter loss of $0.67 per share, which was wider than the Zacks Consensus Estimate of a $0.37 loss but narrower than the $0.85 per share loss a year earlier.

Why it matters — The quarterly results missed analyst revenue and earnings expectations, which ENTA watchers would note as a sign of weaker-than-projected performance.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026

Business Wire · 10 Aug 2026positive

Enanta Pharmaceuticals reported financial results for its fiscal third quarter ended June 30, 2026. The company noted continued momentum across its RSV and immunology programs, including the start of dosing in the LOTUS Phase trial.

Why it matters — A watcher of ENTA would care because the update highlights progress in the company's key clinical programs, including the initiation of the LOTUS trial.

FAQ

Frequently asked questions about ENTA stock

What is the ENTA stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Enanta Pharmaceuticals, Inc. have a median 12-month price target of $20, with estimates ranging from $19 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENTA stock a buy right now?

Of the 5 analysts covering Enanta Pharmaceuticals, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enanta Pharmaceuticals, Inc. 86 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENTA?

As at 12 Sept 2026, Enanta Pharmaceuticals, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will ENTA stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +54.3% from the last close, and Ticker Nerd's factor model ranks Enanta Pharmaceuticals, Inc. 86 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENTA stock forecast for 2030?

No analyst covering Enanta Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $19 to $20 over the next 12 months.

How has ENTA stock performed over the past year?

Enanta Pharmaceuticals, Inc. returned +49.7% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enanta Pharmaceuticals, Inc. do?

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases.

What is the latest news on ENTA?

The most recent item we track (Business Wire, 1 Sept 2026): "Enanta Pharmaceuticals to Participate in September Investor Conferences". Enanta Pharmaceuticals announced that members of its management will participate in two investor conferences in September: the Baird 2026 Global Healthcare Conference (fireside chat on September 15, 2026) and the H.C. Wainwright 28th Annual Global Investment Conference. The company is a clinical-stage biotechnology firm developing small molecule drugs for viral infections and immunological diseases.

Company

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions. Enanta also generates value through its collaboration with AbbVie, including royalty interests tied to glecaprevir, a component of a hepatitis C treatment regimen marketed by AbbVie. The company’s work combines medicinal chemistry, drug discovery, and clinical development to advance oral therapies aimed at areas with significant unmet medical need. Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals plays a specialized role in the biotechnology market by supporting both partnered products and its own pipeline of investigational medicines.

CEO Dr. Jay R. Luly Ph.D. · 120 employees · United States · https://www.enanta.com